ABVC BioPharma (ABVC) vs Lite Strategy (LITS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lite Strategy (LITS) has outperformed ABVC BioPharma (ABVC) over the past year, losing 52.8% versus a loss of 67.8%. Over five years, ABVC leads with a -97.3% price change compared with -98.5% for LITS. Lite Strategy is the larger company by market cap ($24.0 million vs $23.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVC | LITS |
|---|---|---|
| Share price | $0.8663 | $0.8026 |
| Market cap | $23.37M | $23.99M |
| 1-day change | -1.56% | -4.03% |
| YTD return | -59.33% | -39.20% |
| 1-year return | -67.80% | -52.79% |
| 5-year return | -97.29% | -98.46% |
| EPS (TTM) | $-0.20 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $296.00K | — |
| Revenue growth (YoY) | -41.91% | — |
| Net income (latest FY) | $-7.91M | $-71.15M |
| Operating margin | -2415.97% | — |
| Net margin | -2671.81% | — |
| 52-week high | $2.87 | $1.99 |
| 52-week low | $0.707 | $0.69 |
| Distance from 52-week high | -69.82% | -59.67% |
| Average volume | 81.92K | 524.33K |
| Shares outstanding | 26.98M | 29.88M |
| Employees | 16 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LITS has outperformed ABVC by 15.0 percentage points over the past year.
About ABVC BioPharma
ABVC stock →ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Lite Strategy
LITS stock →Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ABVC vs LITS FAQ
Which is bigger, ABVC BioPharma or Lite Strategy?
Lite Strategy (LITS) is larger, with a market capitalization of $23.99M compared with $23.37M for ABVC BioPharma (ABVC).
Which stock has performed better over the past year, ABVC or LITS?
LITS returned -52.79% over the past 12 months, compared with -67.80% for ABVC (price return, excluding dividends). Past performance does not predict future results.
Are ABVC BioPharma and Lite Strategy in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.